Navigation Links
Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
Date:6/20/2013

ring improvements in seizure-free efficacy, with 45 percent indicating a high willingness. Payers also indicate receptivity to new products that increase the percentage of adult treatment-refractory patients successfully completing a conversion to monotherapy trial and/or more-effectively reduce partial-onset seizure frequency as an adjunctive therapy in pediatric treatment-refractory patients. However, 30-40 percent of surveyed MCO pharmacy directors would require a 75 percent improvement over lamotrigine immediate release (GlaxoSmithKline/Juste's Lamictal, other brands, generics) on these metrics to consider reimbursement, the highest level of improvement assessed in the report.

"While our findings suggest that most payers will require that a drug deliver a strong clinical performance in these arenas to inspire coverage, they indicate they will accept price premiums under either scenario, although tier-dependent cost controls are likely," said Decision Resources Business Insights Analyst John Crowley, Ph.D. "Moreover, conjoint analysis signals neurologists' own price sensitivity for products that cost considerably more than current second- and third- generation AED brands, which generally fall within a range of $10-15/day in the United States."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
2. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
3. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
4. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
5. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
6. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
7. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
8. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
9. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
10. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
11. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... LEIDEN, Netherlands, March 8, 2011 Johnson & Johnson (NYSE: ... CRXL ; Swiss Exchange: CRX) today announced that ... Subsequent Offering Period), Johnson & Johnson has acquired 98.89% ... treasury shares held by Crucell) and 98.93% of the issued ...
... 2011 Sequenom, Inc. (Nasdaq: SQNM ) today ... year ended December 31, 2010. (Logo:   http://photos.prnewswire.com/prnh/20040415/SQNMLOGO ... Total revenue for the fourth quarter of 2010 grew 28% ... quarter of 2009. The increase in revenue compared to the ...
Cached Medicine Technology:Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 2Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 3Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 4Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 5Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 6Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 2Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 3Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 4Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 5Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 6Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 8Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 9
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... ... Reduce Errors By 50% or More, **Presented by FDAnews and Ginette M. Collazo, ... Collazo, a 15 year veteran of helping drug, biologic and device firms reduce ...
(Date:7/30/2015)... ... 30, 2015 , ... World Patent Marketing, a vertically integrated ... that can help people during emergencies. , "The worldwide mobile health market revenue ... of World Patent Marketing. "Currently, there are about 97,000 mobile health apps available ...
(Date:7/30/2015)... ... ... In an effort to provide the twenty four hour continuous care desired by ... , The decision will also allow him to spend more time in the office ... admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always provided excellent ...
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual ... Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this with ... its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be disclosing ... discussed in a June 8, 2015 article published by Nasdaq , the powerful ... caused by its computer-driven cars, which such industry players as Tesla CEO Elon Musk ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3
... most common cancers in the world. Although the prognosis ... survival rate for those who receive operative treatment is ... surgical intervention. However, many surviving patients might suffer from ... in their later life. , A research article ...
... agent for treatment of patients with chronic hepatitis ... monotherapy leads to the emergence of lamivudine-resistant hepatitis ... infected with HBV. Sensitive methods for early detection ... decisions in treating patients with HBV infection. , ...
... no shortages here , , WEDNESDAY, Jan. 16 (HealthDay News) ... the safety gaps in the U.S. food system. , ... one federal "superagency" to monitor food safety; beefing up ... the very least, giving the FDA the ability to ...
... builds on success in Eastern Washington, SPOKANE, Wash., ... establishing a larger presence in the Spokane community.,The new ... are already employed by WDS in Spokane. Eventually, the ... tremendous success with our customer service center in,Colville and ...
... Dr. Judah,Folkman, founder of the field of angiogenesis, died ... one of the thousands of lectures,that he gave to ... Folkman was founder and director of the Vascular Biology,Program ... Surgery,and Cell Biology at Harvard Medical School., When ...
... Expected Recurring ... ... Rate ... Stereotaxis, Inc. (Nasdaq:,STXS) today reported that due to the previously delayed European launch of,its partnered ...
Cached Medicine News:Health News:What is the more suitable for early detection of low abundant lamivudine-resistant mutants? 2Health News:U.S. Food Safety: Solutions at a Glance 2Health News:U.S. Food Safety: Solutions at a Glance 3Health News:Washington Dental Service Opens Larger Spokane Office 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 3Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 4Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 2Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 3Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 4
An Antiseptic - Antibacterial Cleanser that helps reduce bacteria that can potentially cause disease.Does not produce the systemic adverse effects associated with iodine or iodine by-products and is ...
... for professional degerming, pre-op and post-op ... combining quaternary and substituted phenolic active ... emollients and surfactants. Unprecedented efficacy on ... in 30 seconds. Techni-Care represents a ...
... Solution is the ... povidone-iodine. It is a ... kills gram-positive and gram-negative ... organisms), as well as ...
... pouches are designed for individual application and ... used in nursing homes, home healthcare settings, ... other hospital departments. This unit dose pouch ... antiseptic, germicidal and cleansing agent. Hydrogen Peroxide's ...
Medicine Products: